Figure 6.

Effects of APS on GR cells with EMT. Cells were treated with gefitinib (G, 1 µM, D1) and/or APS (200 mg/L, D1). A, B. Cell proliferation assays showed that proliferation inhibition rate of GR cells treated with gefitinib and APS was higher than that of GR cells treated with gefitinib. C, D. Cell apoptosis assays showed that after treatment with APS combined with gefitinib, GR cell apoptosis ability was enhanced. Data represented percentage of annexin V single positive (early apoptosis) and annexin V/PI double positive (late apoptosis) cells. Lower left quadrant contains the vital (double negative) population, upper left quadrant contains the damaged (annexin V-/PI+) cells, upper right quadrant contains the late apoptotic (annexin V+/PI+) cells, and lower right quadrant contains the early apoptotic (annexin V+/PI-) population. E, F. Cell migration assays showed that GR cell migration ability was weakened. Data are represented as mean ± SEM (n=3). All data are representative of at least three independent experiments. *P<0.05, **P<0.01, compared to control group. A, C, E. HCC827/GR/EMT cells; B, D, F. PC9/GR/EMT cells.